Articles

Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer

Chi M Nguyen, Paul G Yeh, Mai P Nguyen, et al. Cancer Res Commun. 2025 Oct 1;5(10):1852-1864

Colorectal cancer is a leading cause of cancer-related death and among the costliest cancers to treat in the United States. This study highlights the substantial economic burden of mCRC, with medical and prescription costs nearly twice those of nonmetastatic cases. Among 25,169 patients, 32.8% had metastasis at diagnos... Read More

15 Apr, 2026

Estimating Productivity Loss from Breast and Non-Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method

Kevin Chiu, Joanna P MacEwan, Suepattra G May, et al. MDM Policy Pract. 2022 Aug 3;7(2)

Cancer can have a profound impact on productivity. Traditional approaches to capturing health-related productivity loss focus only on the foregone wages of affected patients, overlooking the losses caregivers can incur. This study estimated the burden of productivity loss among breast cancer (BC) and non-small-cell lun... Read More

15 Apr, 2026

Financial Toxicity Among Patients with Breast Cancer Worldwide: A Systematic Review and Meta-analysis

Ana N Ehsan, Catherine A Wu, Alexandra Minasian, et al. JAMA Netw Open. 2023 Feb 1;6(2):e2255388

Financial toxicity (FT) is the negative impact of cost of care on financial well-being. Patients with breast cancer are at risk for incurring high out-of-pocket costs given the long-term need for multidisciplinary care and expensive treatments. A comprehensive database search was conducted. Of the 11 086 articles retri... Read More

15 Apr, 2026

Estimated Out of Pocket Costs for Patients With Common Cancers & Private Insurance

Liam Rose, Ganesh Rajasekar, Anjali Nambiar, et al. JAMA Netw Open. 2025 Jul 1;8(7):e2521575

Cancer imposes a substantial economic burden on patients that may be worse in patients with higher-stage disease due to the need for more therapy.  The cohort consisted of 46,158 patients (mean age at diagnosis, 46 years; 30,733 female [66.6%]; 2543 Asian [5.5%], 4114 Black [8.9%], 3590 Hispanic [7.8%], and 31 099... Read More

15 Apr, 2026

Economic burden of patients with leading cancers in China: a cost-of-illness study

Ziting Wu , Yiwen Yu, Feng Xie, et al. BMC Health Serv Res. 2024 Sep 27;24(1): 1135

China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China. This cross-sectional cost-of-illness study analyze... Read More

15 Apr, 2026

A Systematic Review of The Economic Burden of Colorectal Cancer

Aug.Abdosaleh Jafari, Fatemeh A Hosseini, Faride S Jalali et al. Health Sci Rep. 2024 Aug 21;7(8):e70002

Colorectal cancer is the third most common cancer in the Western Hemisphere. It is the third most common cancer in men after prostate and lung cancers and the second most common cancer in women after breast cancer. According to some studies, the incidence and prevalence of colorectal cancer is increasing rapidly. ... Read More

15 Apr, 2026

Estimated Out-of-Pocket Costs for Patients with Common Cancers and Private Insurance

Liam Rose, Ganesh Rajasekar , Anjali Nambiar , et al. JAMA Netw Open. 2025 Jul 1;8(7):e2521575

Cancer imposes a substantial economic burden on patients that may be worse in patients with higher-stage disease due to the need for more therapy. This retrospective cohort study used administrative claims data of a large national insurer in the US. The cohort consisted of 46,158 patients age at diagnosis, 46 years; 30... Read More

15 Apr, 2026

Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe

Agnes Brandtmüller , Anne Meiwald , Peter Toth , et al. J Med Econ 2026 Dec;29(1):785-798

Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types with the highest morbidity burden across 28 European countries in 2022. Tracheal, bronchus, and lung cancer, col... Read More

15 Apr, 2026

Projected Impact on Labor Productivity Costs of Cancer Related Premature Mortality in Europe 2018–2040

Marta Ortega Ortega, Paul Hanly, Alison Pearce, et al. Applied Health Economics and Health Policy (2023) 21:877–889

Between 2018 and 2040, cancer is expected to cause around eight million premature deaths (58% male). The cumulative projected productivity costs in this respect are €1.3 trillion, representing an annual average of €58.7 billion, or 0.43% of the EU-27 gross domestic product. Labour productivity costs are projected to de... Read More

15 Apr, 2026

Prevent Cancer 2026 Survey

Cost concerns now rival fear of cancer diagnosis, new survey findsFindings from the Prevent Cancer Foundation’s 2026 Early Detection Survey reveal that concern about unexpected costs of getting routine cancer screenings now rivals the fear of getting diagnosed with cancer. More than one in three U.S. adults (34%) who w... Read More

09 Apr, 2026